^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:PP2 (Src kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Head Neck
    Title:

    Src Inhibitors Suppress the Growth of Papillary Thyroid Carcinoma

    Excerpt:
    A much higher concentration of PP2 and SU6656 is needed to see a significant growth inhibition in K2 cells than in TPC-1 cells. In K2 cells after 4 days of treatment, the cell growth was repressed for 36.5 or 50.9% (p < 0.001) by 5 or 10 μM PP2, or 34 or 52.4% (p < 0.001) by 5 or 10 μM SU6656, respectively, when compared to untreated cells...
    DOI:
    10.1002/hed.23316